Guggenheim Rates Zevra Therapeutics (ZVRA) buy, $29 Price Target
Guggenheim's analyst Eddie Hickman reaffirms a buy rating for Zevra Therapeutics with a price target of $29 on June 10, 2026, a 129.25% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Guggenheim rated Zevra Therapeutics, Inc. ($ZVRA) "buy" with a $29 price target on June 10, 2026.
Since the rating, $ZVRA is down 6.6% after 1 week, down 1.1% after 1 month and down 26.4% to date (from the $13.50 close on Jun 10, 2026).
ZVRA
Zevra Therapeutics, Inc.
Key Points
- Guggenheim reiterated its buy rating on Zevra Therapeutics, Inc. with a target price of $29, up from the current share price of $12.65.
- Guggenheim's $29 price target implies 129.25% upside from Zevra Therapeutics, Inc.'s ($ZVRA) current $12.65 share price.
- Zevra's stock trades well above its 52-week low of $7.88, reflecting a positive outlook amid ongoing clinical trials for its rare disease treatments.
- The consensus among analysts remains strong, with a recommendation key of 'strong buy' and a mean price target of $25 from nine analysts.
Get $ZVRA trade alerts by text
We text you when insiders, Congress or big funds trade $ZVRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zevra Therapeutics, Inc. alert may contain errors. Disclosures
Guggenheim Affirms Buy Rating
On June 10, 2026, Guggenheim reiterated its buy rating on Zevra Therapeutics, Inc. (ZVRA) with a price target of $29. The stock was trading at $12.65 at the time of the announcement, indicating a significant upside potential.
Analysts Set New Price Targets
Guggenheim's recent call aligns with a generally positive sentiment on Wall Street. Other firms like HC Wainwright & Co. have also reiterated their buy rating with a target of $26 on August 20, 2026. Citizens maintained a market outperform rating with a target of $28 on August 6, 2026, whereas Canaccord Genuity lowered its target to $20 but still holds a buy rating. This reflects a diverse range of opinions, with the consensus leaning towards optimism for Zevra's future.
How Zevra Therapeutics, Inc. Stock Has Traded
Zevra Therapeutics' stock has shown resilience, trading above its 50-day moving average of $11.63 and its 200-day average of $10.45. The stock is also currently above its 52-week low of $7.88, suggesting confidence in its recovery potential. With the recent reaffirmation of buy ratings, investor interest may continue to grow.
$ZVRA price target
Zevra Therapeutics, Inc. daily closes and this analyst's $29 target. Not advice.
What Zevra Therapeutics, Inc. Does
Zevra Therapeutics focuses on developing treatments for rare diseases in the U.S. Its lead product candidate, KP1077, is under Phase 3 trials for idiopathic hypersomnia and narcolepsy. The company's innovative approach aims to address significant unmet medical needs, making this analyst support noteworthy for its future prospects.
What to Watch at Zevra Therapeutics, Inc.
Investors should keep an eye on Zevra's upcoming earnings report scheduled for November 4, 2026. As a reminder, Guggenheim's rating reflects the analyst's view as of June 10, 2026, and may not represent the current market position.
Related Filing Alerts
Source: Guggenheim's rating change on $ZVRA (Jun 10, 2026). Written by software, not financial advice. How we make alerts